03 Profile
Vital Signsby Bridgehead
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Diabetes
Thomas Seck: no photograph is held, so the academic plate is shown instead.
Academic
Thomas Seck
M.D., senior vice president of product development, Lilly Cardiometabolic
1
0
0
0
0
1
1
1
Apr 2026MayJuneJulyAugSeptOctNovto date
4
press citations on 2 topics since 16 Apr 2026 · last quoted 9 Nov 2026
02 Quoted on · 2 of 29 topics
Thomas Seck: key facts
- Kind of voice
- Academic
- Role
- M.D., senior vice president of product development, Lilly Cardiometabolic
- Quoted on
- Diabetes, Respiratory (asthma/COPD)
- Tracked press citations
- 4
- Most recently quoted
- 9 Nov 2026
- First quoted
- 16 Apr 2026
04 The signal · where Thomas Seck sits on diabetes
Ranked 48= of 100 voices quoted in the press on diabetes, level with 35 others on 3 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Douglas TwenefourClinicianHead of Clinical, Diabetes UK36 - 2
Dr Elizabeth RobertsonSector leaderDirector of Research and Clinical, Diabetes UK20 - 3=
Helen KnightRegulatorDirector of Medicines Evaluation, National Institute for Health and Care Excellence (NICE)15 - 48=Dr Simon CorkAcademicsenior lecturer in physiology at Anglia Ruskin University3
- 48=Donald GrantClinicianGP and Senior Clinical Advisor at The Independent Pharmacy3
- 48=Thomas SeckAcademicM.D., senior vice president of product development, Lilly Cardiometabolic3
- 48=Anna ClarkeClinicianclinical research nurse3
- 48=Mark VerdantSector leaderclinical trials support officer at Somerset NHS Foundation Trust3
Showing the leaders and the ranks around 48=, of 100 voices · See every voice on the topic →
05 On the record · press
What Thomas Seck has said
By outlet · linked articles
- fiercepharma.com4
Where Thomas Seck has been quoted
- 01Lilly looks to gird Foundayo label after late-stage win in sleep apneafiercepharma.com · 9 Nov 2026
- 02Lilly gives deeper glimpse at Foundayo's heart-helping odds in diabetes, obesity phase 3fiercepharma.com · 1 Oct 2026
- 03Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milanfiercepharma.com · 29 Sept 2026
- 04Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallelfiercepharma.com · 16 Apr 2026
Verbatim
“OSA is one of the most serious complications of obesity and is closely linked to cardiovascular disease. In ATTAIN-OSA, Foundayo significantly improved sleep apnea along with key cardiovascular risk factors, showing its potential to treat conditions that drive heart disease.”
“reinforces our confidence that Foundayo could change how physicians and patients approach the treatment of type 2 diabetes”
“In a head-to-head Phase 3 clinical trial, Zepbound 10 mg and 15 mg delivered greater weight loss than Wegovy 1.7 mg and 2.4 mg, and a new indirect treatment comparison suggests the same doses of Zepbound may outperform Wegovy HD, as well”
“ACHIEVE-4 adds a new dimension to that evidence -- cardiovascular safety and a lower observed risk of all-cause death in patients who carry elevated cardiovascular risk.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 13 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.